descriptionPublicationkeyboard_double_arrow_right Article 30 Jul 2015 English Publisher:American Society of HematologyJournal:Blood, volume 126, pages 564-566 (issn: 0006-4971, eissn: 1528-0020,

Authors: M. Teresa Cibeira; Joan Bladé;

doi: 10.1182/blood-2015-06-648113

pmid: 26228167

Upfront CyBorD in AL amyloidosis

- Summary
- Subjects
- Metrics

Abstract

In this issue of Blood , [Palladini et al][1] report on the outcome of a large series of 230 patients with systemic immunoglobulin (Ig) amyloid light chain (AL) amyloidosis treated frontline with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) at 2 referral centers.[1][2] ![Figure][3]

Related Organizations

Keywords

Pyrazines, Humans, Amyloidosis, Boronic Acids, Cyclophosphamide, Dexamethasone

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	7
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average